Who We Are
The Remy Peptides Research Team is the editorial board responsible for every research article published on this site. Our team includes pharmacologists, analytical chemists, and regulatory analysts with expertise across the metabolic peptide pipeline.
Every article in the Research Library undergoes multi-stage review for factual accuracy, proper citation of peer-reviewed sources, and compliance with our editorial policy.
Editorial Leadership
Editorial Standards
All content follows the standards documented on the Research Standards page, including:
- Primary sourcing from peer-reviewed journals (NEJM, Lancet, Diabetes Care)
- Clinical trial data cited with ClinicalTrials.gov registration numbers
- Regulatory status verified against FDA, EMA, and MoHAP databases
- No therapeutic claims — all content framed for research context
- Regular updates when new trial readouts or regulatory decisions are published
Coverage Areas
- GLP-1 and multi-receptor agonist pharmacology
- Obesity drug approval timelines and regulatory pathways
- Peptide stability, storage, and analytical verification
- UAE regulatory compliance (MoHAP Circular 17/2022)
- Comparative efficacy data across the metabolic drug pipeline
Output
- 50+ peer-reviewed research articles published
- Ongoing coverage of Phase 2/3 trial readouts and FDA advisory committees
- Regular updates to approval trackers, dosage guides, and comparison analyses
Related Pages
- Research Library — 50+ peer-reviewed research articles
- Editorial Policy — content creation and review process
- Research Standards — verification and compliance framework
- About Remy Peptides — company background and mission